Lung Cancer Clinical Trials in Ohio

Showing 321-340 of 803 trials

Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity

NCT04954885

This study evaluates gut microbiome and functional status as modifiable biomarkers in predicting immunotherapy response and toxicity in patients with stage IV non-squamous non-small cell lung cancer receiving pembrolizumab alone or in combination with pemetrexed and carboplatin on the INSIGNIA trial. The goal of this study is to estimate the extent to which future interventions that seek to rationally modify the gut microbiome and/or functional status can improve outcomes.

Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+2 more

Ohio State University Comprehensive Cancer Center2 participantsStarted May 2021

Columbus, Ohio, United States

Approved For Marketing32 miles

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Non Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+4 more

Eli Lilly and Company

Goodyear, Arizona, United States • Scottsdale, Arizona, United States • Duarte, California, United States +61 more locations

PreviousPage 17 of 41Next

Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Lung Cancer Trials in Other Cities

Comprehensive Outcomes for After Cancer Health

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Pulmonary Rehabilitation Before Lung Cancer Resection

Avelumab in First-line NSCLC (JAVELIN Lung 100)

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Other Conditions in Ohio